Efficacy and tolerability of tamsulosin alone and in combination with dutasteride in patients of benign prostatic hyperplasia

JK Science

Volumn 14, Issue 3, 2012, Pages 134-138

  Arora, Sapna ^b   Khajuria, Vijay ^b   Kohli, Kamlesh ^b   Gupta, Sunil ^a   Tandon, Vishal R ^b  

^a Deptt of Pharmacology and Therapeutics and Surgery   (India)

^b Govt Medical College Jammu   (India)

Author keywords

AUA symptom score; BHP; Dutasteride; Tamsulosin

Indexed keywords

ATROPINE PLUS BENZOIC ACID PLUS HYOSCYAMINE PLUS METHENAMINE PLUS METHYLENE BLUE PLUS SALICYLIC ACID PHENYL ESTER; DUTAST; DUTASTERIDE; TAMSULOSIN; UNCLASSIFIED DRUG;

ADULT; AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX; ARTICLE; AVERAGE URINE FLOW RATE; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ECHOGRAPHY; EJACULATION DISORDER; HUMAN; LIBIDO DISORDER; MALE; MAXIMUM URINE FLOW RATE; MONOTHERAPY; NOSE OBSTRUCTION; PARALLEL DESIGN; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; PROSTATE VOLUME; RANDOMIZED CONTROLLED TRIAL; RENAL SYSTEM PARAMETERS; RESIDUAL URINE; SIDE EFFECT; TIME TO PEAK URINE FLOW; URINE FLOW TIME; URINE VOLUME; UROFLOWMETRY; VITAL SIGN; VOIDING TIME;

EID: 84875341922     PISSN: 09721177     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. De la Rosette JJ, Kortmann BB, Rossi C, et al. Long-term risk of retreatment of patients using alpha blockers for lower urinary tract symptoms. J Urol 2002;167: 1734-9
2. Horvath K, Walter G, Varga A and Romics I. A novel approach to the treatment of BPH. BJU 2006; 97: 1252-55
3. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The measurement Committee of the American Urological Association. J Urol 1992;148:1549-57
4. Nehra A. Selecting therapy for maintaining sexual function in patients with BPH. BJU Int 2005; 96: 237-43
5. Foley C L, Kirby R S. 5 ARI: What is new? Curr Opin Urol 2003; 13(1): 31-37
6. Abrams P, Schulman C C, Voage S. Tamsulosin, a selective?-1A adrenergic antagonist. A randomized controlled trial in patients with BPH. The European Tamsulosin Study Group. Br J Urol 1995; 76: 325-26
7. Chappel CR. Selective alpha 1-adrenoceptor antagonists in BPH. Rationale and clinical experience. Eur Urol 1996; 29: 129-44
8. Narayan P, Lepor H. Long term open label phase III multicenter study of tamsulosin in BPH. Urology 2001; 57: 466-70
9. Yanardag H, Goktas S, Kibar Y, Kilic S, Erduran D. Intermittent tamsulosin therapy in men with LUTS. J Urol 2005; 173: 155-57
10. Kurita Y, Ushiyama T, Suzuki K, Fujita K, Kawabe K. Transition zone ratio and PSA density. The index of response of BPH to an alpha-blocker. Int J Urol 1996; 3: 361-66
11. Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Origasa H. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of BPH; a randomized controlled trial. BJU Int 2005; 96: 581-86
12. Lepor H, William O W, Barry M J, et al. The efficacy of Terazosin, Finasteride or both in BPH. N Engl J Med 1996; 335: 533-39
13. Debruyne F M J, Jardin A, Collol D, et al. Sustained release Alfuzosin, Finasteride and the combination of both in the treatment of BPH. Eur Urol 1998; 34: 169-75
14. Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride alone or in combination in the treatment of symptomatic BPH the PREDICT trial. Urology 2003; 61: 119-26
15. Chapple C R, Wyndaele J J, Nordling J, et al. Tamsulosin The first prostate selective?1A-adrenoceptor antagonists. Eur Urol 1996; 29; 155-67
16. Milani S, Djavan B. Lower Urinary tract symptoms suggestive of BPH: latest update on?1-adrenoceptor antagonists. BJU Int 2005; 95(4): 29-36
17. Flannery M T, Ramsdell J, Ranhosky A, Davidai G, Ruoff G. Efficacy and safety of Tamsulosin for BPH: Clinical experience in primary care setting. Curr Med Res Opin 2006; 22(4); 721-30
18. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, Van Vierssen OB on behalf of the SMART-1 investigator group. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor-dutasteride. Eur Urol 2003; 44: 461-66
19. Gittelmann M, Ramsdell J, Young J, McNicholas T. Dutasteride improves objective and subjective disease measures in men with BPH and modest or severe prostate enlargement. J Urol 2006; 176: 1045-50
20. Kawabe KE. Efficacy and safety of Tamsulosin in the treatment of BHP. BJU 1995; 76(1): 63-67
21. Hofner K, Claes H, De Reijke TM, Folkestad B, Speakman MJ. for the European Tamsulosin Study Group. Tamsulosin 0.4 mg once daily! Effects on sexual function in patients with LUTS suggestive of BHP. Eur Urol 1999; 36: 335-41
22. Giuliano F. Impact of medical treatment for BHP on sexual function. B J U Int 2006; 97(2): 34-38